©LSOphoto via Canva.com
Asthma Inhaler Switch Will Affect Millions Beginning in January
December 29, 2023
The asthma inhaler Flovent, made by GSK, will disappear from pharmacy shelves beginning in January. A generic version will replace Flovent. However, doctors have expressed concern that patients who rely on the medication may experience delays in switching to other medical alternatives and getting them covered by insurance as the new year begins.
The potential for disruption in care is causing distress among users of the drug. However, physicians who treat patients with asthma say the authorized generic will work just as well as the branded drug.
Thank you @megtirrell and @CNN for putting #asthma and the #Flovent discontinuation in the spotlight 🙏 https://t.co/mN5fJcgRT3
— Robyn Cohen MD,MPH (@RobynCohenMD) December 28, 2023
The primary issue concerning users of the drug is that the generic version may be covered less widely than Flovent. CNN quoted Dr. Robyn Cohen, a pediatric pulmonologist at Boston Medical Center, who calls Flovent the go-to drug when treating those with asthma.
“This medication has been the most commonly used inhaled medication for the past 25 or 30 years,” said Cohen. “It’s the one that, overwhelmingly, pediatricians reach for when they decide that their patient needs a daily preventive medication. The fact that it’s being discontinued is going to be a huge shock to the system for patients, for families and for doctors.”
A spokeswoman for GSK said the company introduced generics of Flovent HFA, an inhalation aerosol, in May 2022 and Flovent Diskus, an inhalation powder, in October 2023. Plans to phase out the branded versions of certain inhalers begin Jan. 1, 2024.
The spokeswoman said that the authorized generics “will provide patients in the US with potentially lower cost alternatives of these medically important products.” A provision in the 2021 American Rescue Plan states that starting Jan. 1, 2024, drugs that have been subject to significant price increases over time could end up incurring rebates to Medicaid that are greater than their price. Doctors are urging patients to get new prescriptions if needed and sort out coverage issues as soon as possible.
Recent News
Massive Data Breach Hits Ticketmaster, Affecting 560 Million Customers
Ticketmaster has fallen victim to a significant cyber-attack, potentially compromising the data of up to 560 million customers. The breach was confirmed by Ticketmaster’s parent company, Live Nation, which revealed that a notorious hacking group, ShinyHunters, is behind the attack. The hackers are demanding a ransom of approximately £400,000 to prevent the data from being sold on the dark web.
Toyota Recalls 100,000+ Tundra and Lexus LX SUVs Over Engine Debris Issue
Toyota has announced a recall for over 100,000 Tundra pickups and Lexus LX SUVs in North America due to potential engine issues caused by machining debris. This recall affects certain 2022-2023 models of the Tundra and LX, which are equipped with the new V6 twin-turbo engine. The V6 twin-turbo engine has faced considerable scrutiny regarding its reliability, especially when compared to the previous naturally aspirated V8 engines.
Wordle and Worldle Battle Over Names
A legal dispute has erupted between the wildly popular word game Wordle and the lesser-known geography game Worldle, centering on the similarity of their names. Wordle, which was developed by Josh Wardle in 2021 and later acquired by the New York Times in 2022 for a substantial sum, has gained immense popularity. In this game, players have six attempts to guess a five-letter word.
FDA Issues Recall for Crecelac Goat Milk Infant Formula
The U.S. Food and Drug Administration (FDA) has issued a safety alert regarding Crecelac Goat Milk Infant Formula and other infant formula products imported and distributed by Dairy Manufacturers Inc. The alert highlights Cronobacter contamination concerns with Crecelac Infant Powdered Goat Milk Infant Formula. Although Dairy Manufacturers Inc. initiated a recall on May 24, 2024, due to non-compliance with FDA regulations, new findings of Cronobacter contamination have prompted further action.